ClinicalTrials.gg
CompletedNCT04535960NATRIURETICUpdated Oct 26, 2026

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

A Phase 2 interventional study of Empagliflozin 25 MG + Liraglutide 1.8 MG and Liraglutide 1.8 MG + Empagliflozin 25 MG in Type 2 Diabetes Mellitus, sponsored by University Health Network, Toronto. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Mar 2019, registered Feb 2020).
Updated Oct 26, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
125th of 130
6 · median 79
Started
2019
with 5 others
Phase 2
17 of 130
none open now
Registered
78th of 130
by date

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 125th largest by enrollment, is one of 6 that started in 2019, is one of 17 in phase 2, and was the 78th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study aims to provide essential mechanistic insights into natriuretic and hemodynamic effects of SGLT2i and GLP-1RA agents in T2D patients. Ultimately, by obtaining physiological data in T2D patients without HF, our aims are to gain insight into how the use of this combined therapy may be used in T2D with HF in future work.

Read the detailed description

Type 2 diabetes (T2D) is an epidemic that afflicts more than 350 million people world-wide. Despite the use of existing medical therapies, T2D continues to cause significant morbidity and mortality, leading to large societal and financial costs to Canadians.

Newer agents called sodium glucose co-transporter-2 inhibitors (SGLT2i) have been developed to improve glycemic control and lower hemoglobin A1c by increasing glycosuria. SGLT2i also reduce blood pressure and albuminuria in T2D - possibly through natriuresis. Importantly, a landmark trial "EMPA-REG OUTCOME" demonstrated that the SGLT2i empagliflozin is the first anti- hyperglycemic agent to reduce mortality and heart failure (HF) risk, and also to decrease the risk of progressive diabetic nephropathy.

Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is a subcutaneous drug, used for treating T2D patients. Recently, this drug was also able to reduce cardiovascular endpoints in the LEADER trial. Furthermore, liraglutide attenuated the risk of progressive albuminuria as well. GLP-1RAs induce natriuretic effects, but have not been shown to reduce HF risk. Their positive cardiovascular effects are probably due to reduction in atherosclerotic events.

T2D patients are at high risk for development of both HF and atherosclerotic diseases. Given that SGLT2i and GLP-1RA seem to reduce cardiovascular outcomes via different approaches, combining these two agents in the treatment of T2D is an appealing new strategy. In this project, we aim to combine GLP-1RA and SGLT2i therapies in T2D patients without HF and compare renal and cardiovascular physiological measures in these patients, such as renal function, neurohormonal activation, blood pressure, arterial stiffness, and systemic vascular resistance. This could give a better understanding on the action of the combination therapy in T2D, support future mechanist trials with patients with HF, and give support to the development of large clinical trials on this topic.

Study design: Open-label, exploratory, randomized (with randomization concealment), pilot mechanistic trial, with two groups and 2 sequential treatments within each group.

Study population: Male and female subjects with T2D, 18 years old or older, with eGFR ≥30 mL/min/1.73m2, as described in the full protocol.

Intervention: Patients will be randomized to initial therapy with empagliflozin 25mg PO daily or liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks and patients in the liraglutide group will also receive empagliflozin 25mg PO daily for 6 weeks (combination therapy).

Primary Objective: Comparison of proximal tubular natriuresis (measured by FENa+, fractional excretion of sodium) after 6 weeks of SGLT2i monotherapy vs FENa+ after 6 weeks of combination therapy (SGLT2i + GLP-1RA) AND comparison of FENa+ after 6 weeks of GLP1-RA monotherapy vs FENa+ after 6 weeks of combination therapy (GLP-1RA + SGLT2i).

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients visit the outpatient clinic on a more regular basis than standard patient care - i.e. at study inclusion and at each study visit for clinical assessment. Blood work for physiological assessments, renal function tests and cardiovascular assessments will be obtained as described in the protocol. 24hr urine will be collected one day prior to the hospital visit. No other invasive measurements will be executed. Patients receive restitution of all travel costs and also a financial aid for 3 visits. Patients receive no priority in treatment of other diseases in the clinic during this study. There are no other direct benefits for the patients to be included and participation is on a voluntary basis.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • SGLT2 inhibition
  • GLP-1 receptor agonist
  • type 2 diabetes mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women diagnosed with T2D ≥6 months prior to ;
  2. ≥30 mL/min/1.73m2;
  3. Age >18 years;
  4. 7.0%-12.0%;
  5. (BMI) 18.5-40.0 kg/m2;
  6. Stable HbA1c, measured 2-12 months prior to screening, within 5% of baseline value;
  7. Blood pressure ≤160/100 mmHg at screening, >90/60 mmHg;
  8. Stable on dose of ACE inhibitor, angiotensin receptor blocker or renin inhibitor for at least 2 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Type 1 Diabetes;
  2. Leukocyte and/or nitrite positive urinalysis that is untreated;
  3. Severe hypoglycaemia within 2 months prior to screening;
  4. History of hypoglycaemia unawareness based on investigator judgement;
  5. Unstable coronary artery disease with acute coronary syndrome, percutaneous intervention or bypass surgery within 3 months;
  6. valvular disease subject to PI/Sub PI's discretion;
  7. Congestive heart failure subject to PI/Sub PI's discretion;
  8. Bariatric surgery or other surgeries that induce chronic malabsorption within one year;
  9. Anti-obesity drugs or diet regimen and unstable body weight three months prior to screening;
  10. Treatment with systemic ;
  11. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells;
  12. Pre-menopausal women who are nursing, pregnant, or of and not practicing an acceptable method of ;
  13. Participation in another trial with an drug within 30 days of ;
  14. Alcohol or drug abuse within three months prior to informed consent that would interfere with trial participation or any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement;
  15. Liver disease, defined by serum levels of , aspartate transaminase, or alkaline phosphatase >3 x as determined during screening;
  16. Medical history of cancer or treatment for cancer in the last five years prior to screening;
  17. History of pancreatitis;
  18. Personal of family history of medullary thyroid cancer or MEN2B;
  19. Tachycardia, HR >100;
  20. Use of SGLT2i, GLP-1RA or DPP-4i within the past 1 month (1-month minimum is allowed);
  21. History of gastroparesis;
  22. Known intolerance to SGLT2i or GLP-1RA;
  23. Allergy to iodine-based substances if receiving iohexol for measures.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Liraglutide

    Liraglutide Subcutaneous Total Dose 1.8mg daily for 6 weeks

    Drug: Empagliflozin 25 MG + Liraglutide 1.8 MG · Drug: Liraglutide 1.8 MG + Empagliflozin 25 MG

  • Experimental
    Empagliflozin

    Empagliflozin Tablets Total Dose 25mg daily for 6 weeks

    Drug: Empagliflozin 25 MG + Liraglutide 1.8 MG · Drug: Liraglutide 1.8 MG + Empagliflozin 25 MG

Interventions

  • DrugEmpagliflozin 25 MG + Liraglutide 1.8 MG

    Drug page: EmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.

    Also known as: Generic names are above, listed

  • DrugLiraglutide 1.8 MG + Empagliflozin 25 MG

    Drug page: LiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.

    Also known as: Generic names are above, listed

06

What researchers measure

Primary outcomes

  1. Proximal tubular natriuresis

    Measured by fractional excretion of sodium

    Time frame: up to 12 weeks

Secondary outcomes

  1. Glomerular Filtration Rate

    GFR

    Time frame: Glomerular Filtration Rate (GFR, based on plasma iohexol clearance) will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

  2. Systolic blood pressure

    SBP

    Time frame: Systolic blood pressure (SBP) will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

  3. Body weight

    Kilograms

    Time frame: Body weight will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

  4. Arterial stiffness

    Measured using a Sphygmocor device

    Time frame: Arterial stiffness will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

  5. Systemic vascular resistance

    Measured using non-invasive cardiac output monitor (NICOM)

    Time frame: Systemic vascular resistance will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

  6. Urinary concentration of the renin-angiotensin aldosterone system (RAAS) markers

    Measured using ELISA

    Time frame: Outcome will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

  7. Urinary EGF,FGF2,Eotaxin,TGFa,G-CSF,Flt-3L,GM-CSF,Fractalkine,IFNa2,IFNy,GRO,IL10,MCP-3,IL-12P40,MDC,IL-12P70,PDGF-AA,IL-13,PDGF-BB,IL-15,sCD40L,IL-17A,IL-1RA,IL1a,IL9,IL1B,IL2,IL3,IL4,IL5,IL6,IL7,IL8,IL10,MCP-1,MIP-1a,MIP-1B,RANTES,TNFalpha,TNFB,VEGF

    41-plex chemo/chemokine profile assay: urinary

    Time frame: Outcome will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

07

Study locations

1 site
  • Renal Physiology Laboratory
    Toronto, Ontario, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Mar 2021, 24 months.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 24 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jan 2019 → Mar 2019, primary completion Oct 2023 → Mar 2021 and completion Oct 2023 → Mar 2021.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2020
First posted
Sep 2, 2020
StartActual
Mar 14, 2019was Jan 2019
Primary completionActual
Mar 16, 2021was Oct 2023
CompletionActual
Mar 16, 2021was Oct 2023
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Start date
Jan 24, 2019→Mar 14, 2019
Oct 26, 2026
Primary completion
Oct 2023→Mar 16, 2021 (actual)
Oct 26, 2026
Study completion
Oct 2023→Mar 16, 2021 (actual)
Oct 26, 2026
Enrollment
36 (estimated)→6 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Completed
    Start date Jan 24, 2019→Mar 14, 2019
    Primary completion Oct 2023→Mar 16, 2021 (now actual)
    Study completion Oct 2023→Mar 16, 2021 (now actual)
    Enrollment 36 (estimated)→6 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04535960
Responsible party
David Z.I. Cherney (Associate Professor of Medicine, Clinician Scientist, University Health Network, Toronto) — Principal investigator
First posted
Sep 2, 2020
Start date
Mar 14, 2019
Primary completion
Mar 16, 2021
Completion
Mar 16, 2021
Last update
Oct 26, 2026

Study contacts

David ZI Cherney, MD PhD FRCPC
principal investigator · University Health Network, Toronto General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Liraglutide

Start the discussion